France’s Sanofi has cut back the size of its corporate line, replacing an outstanding €5.8bn revolver due to expire next year with a €3bn one year plus one plus one facility. The group’s vice-president of treasury finance, Olivier Klaric, had told EuroWeek that he would have been happy
...
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: subs@globalcapital.com
Corporate access
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.
